Testosterone patch approved in Denmark:
This article was originally published in Clinica
The Swedish pharmaceutical company, Astra is distributing TheraTech's transdermal testosterone patch in Denmark after receiving Danish National Health Board approval this month. Known as Atmos in Scandinavia and as Androderm in the US and the UK, the patch is for the treatment of male hypogonadism, insufficient testosterone production. The patch received US FDA approval last September. It is marketed in the US and the UK by SmithKline Beecham (see Clinica No 722, p 20). Astra, which is based in Sodertalje, has been marketing the product in Sweden since August.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.